PubMed Health⌕ Search

PubMed · 12175211

Ligand-localized electron trapping at sensitized semiconductor interfaces.

Abstract

Nanocrystalline (anatase), mesoporous TiO2 thin films were derivatized with [Ru(bpy)2(deebq)](PF6)2 or [Os(bpy)2(deebq)](PF6)2, where bpy is 2,2'-bipyridine and deebq is 4,4'-diethylester-2,2'-biquinoline. Both compounds bind to the nanocrystalline TiO2 films with typical limiting surface coverages of 7 (+/-2) x 10-8 mol/cm2. Electrochemical measurements show that the first reduction of these compounds (-0.60 V vs SCE) occurs prior to TiO2 reduction. Steady-state illumination in the presence of the sacrificial electron donor triethylamine leads to the appearance of the reduced compound, MII(deebq-)(bpy)2+/TiO2. Neither the photoluminescent excited states or the reduced forms of these compounds inject electrons efficiently into TiO2. Transient absorption measurements after a approximately 10-ns laser pulse, reveal greater than 80% MLCT excited states and a smaller fraction of extremely long-lived charge-separated state intermediates assigned to equal concentrations of MII(deebq-)(bpy)2+/TiO2 and MIII(deebq)(bpy)23+/TiO2. The results are consistent with a mechanism of ultrafast electron injection followed by ligand-localized trapping on a second compound. The quantum yield for formation of the charge-separated states (phiCSS) is excitation wavelength dependent. With 417 nm excitation, phiCSS(417) = 0.14 +/- 0.03, and this decreases with 532.5 nm excitation, phiCSS(532.5) = 0.08 +/- 0.03, and 683 nm excitation for M = Os, phiCSS(683) = 0.05 +/- 0.01. Electron transfer to yield ground-state products, MII(deebq-)(bpy)2+/TiO2 + MIII(deebq)(bpy)23+/TiO2 --> 2 MII(deebq)(bpy)22+/TiO2, occurs with a driving force of 2.05 eV for Ru/TiO2 and 1.64 eV for Os/TiO2. The dynamics of this process were quantified on a millisecond time scale and were found to follow second-order kinetics. The intermediates are sufficiently long-lived that continued pulsed excitation at 10 Hz leads to high concentrations and the formation of transient images on the semiconductor surface that are easily observed by the naked eye.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Paul G Hoertz, David W Thompson, Lee A Friedman, Gerald J Meyer. 2002-08-21. Ligand-localized electron trapping at sensitized semiconductor interfaces.. https://doi.org/10.1021/ja0268478

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗